








Approval, Pricing & Reimbursement Status of in EU4 + UK, US & Japan

	(EUR)							
ZOLGENSMA	Regulatory Approval	May 2018					May 2019	May 2020
	Ex-Factory Price (per pack)	1,945,000	N/ A	2,155,124	1,945,000	2,112,445	2,087,281	1,064,000
	Access & Reimbursement	No Additional Benefit	SMR (Important); ASMR III Ongoing ATU	Full Innovative Status Payment at Result Scheme	Strict eligibility criteria and re-evaluation based on clinical outcomes	MAA	-	-
LIBMELDY	Regulatory Approval	Dec 2020					N/ A	?
	Ex-Factory (per pack)	2,475,000.000	Under Negotiation	2,875,000.000	Under Negotiation	3,383,443.75	N/ A	?
	Access & Reimbursement	Major Additional Benefit	SMR (Important); ASMR III	Full Innovative Status	Ongoing Evaluation AEMPS	MEA (PAS) after initial negative recommendation	N/ A	?

■ Approved/ Reimbursed
 ■ Reimbursed with significant restrictions
 ■ Not Approved/ Reimbursed
 ■ Not Applicable